PEG-Lysostaphin Conjugates for Extended Half-Life
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Lysostaphin, a potent antimicrobial agent, has a short half-life and requires frequent administration, leading to immunogenic responses and painful injections due to its foreign protein nature, necessitating the development of conjugates with water-soluble polymers to extend its duration and reduce immunogenicity.
Innovation Solution
Conjugates of lysostaphin with water-soluble polymers, such as polyethylene glycol (PEG), using degradable linkages like hydrolyzable esters or enzymatically degradable bonds, are created to prolong the agent's half-life and reduce immunogenicity, allowing for less frequent dosing and fewer injections.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If lysostaphin is administered frequently to maintain antimicrobial activity, then the duration of action is improved, but the immunogenic response increases and patient comfort deteriorates
Solution Approach 1:
The patent applies PEGylation technology by conjugating polyethylene glycol (PEG) chains to lysostaphin molecules, creating a composite structure that combines the antimicrobial properties of lysostaphin with the immunoprotective and half-life extending properties of PEG. This composite material approach directly resolves the contradiction by providing both extended duration of action and reduced immunogenicity simultaneously
Solution Approach 2:
The PEG polymer acts as an intermediary substance between the immune system and the lysostaphin antigen. The PEG chains form a steric barrier that prevents immune cells from recognizing and attacking the lysostaphin, thereby mediating protection against immunogenic responses while maintaining the therapeutic activity of the antimicrobial agent
2Duration of action of moving object
If lysostaphin is administered frequently to maintain antimicrobial activity, then the duration of action is improved, but the number of injections increases causing patient discomfort
Solution Approach 1:
The PEG-lysostaphin conjugate creates a composite material with extended circulation half-life, allowing the drug to remain effective in the body for longer periods. This eliminates the need for frequent dosing and reduces the number of painful injections required, directly improving ease of operation while maintaining duration of action
3Duration of action of moving object
If PEGylation is used to extend half-life, then the duration of action is improved, but the complexity of conjugate formation increases
Solution Approach 1:
The patent employs parameter changes by modifying the PEG chain characteristics (molecular weight, degree of substitution, attachment site) to optimize the balance between half-life extension and manufacturing complexity. By systematically varying these parameters, the invention achieves extended duration of action while maintaining feasible conjugate formation processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugates effectively prolong the antimicrobial agent's half-life, decrease the frequency of administration, and minimize immunogenic responses, maintaining significant antimicrobial activity while reducing the burden of frequent injections.
Implementation Method 1
the degradable linkage is either a hydrolyzable linkage or an enzymatically degradable linkage. The linkages include a hydrolyzable moiety selected from a carboxylate ester, a phosphate ester, a carbamate, an anhydride, an acetal, a ketal, an acyloxyalkyl ether, an imine, an orthoester, a thioester, a thiolester, or a carbonate.
Implementation Method 2
the degradable linkage is either a hydrolyzable linkage or an enzymatically degradable linkage
Data Source
Figure 1
Figure 2
Figure 3
AI summary
Provided herein are water-soluble polymer conjugates and polymer-based compositions of antimicrobial agents. Also provided are methods for synthesizing and administering such conjugates and compositions.